Literature DB >> 27288568

Ras signaling through RASSF proteins.

Howard Donninger1, M Lee Schmidt2, Jessica Mezzanotte3, Thibaut Barnoud3, Geoffrey J Clark4.   

Abstract

There are six core RASSF family proteins that contain conserved Ras Association domains and may serve as Ras effectors. They lack intrinsic enzymatic activity and appear to function as scaffolding and localization molecules. While initially being associated with pro-apoptotic signaling pathways such as Bax and Hippo, it is now clear that they can also connect Ras to a surprisingly broad range of signaling pathways that control senescence, inflammation, autophagy, DNA repair, ubiquitination and protein acetylation. Moreover, they may be able to impact the activation status of pro-mitogenic Ras effector pathways, such as the Raf pathway. The frequent epigenetic inactivation of RASSF genes in human tumors disconnects Ras from pro-death signaling systems, enhancing Ras driven transformation and metastasis. The best characterized members are RASSF1A and RASSF5 (NORE1A).
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Apoptosis; NORE1A; RASSF1A; Ras; Signaling; p53

Mesh:

Substances:

Year:  2016        PMID: 27288568      PMCID: PMC5034565          DOI: 10.1016/j.semcdb.2016.06.007

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  174 in total

1.  The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2-DAXX-HAUSP complex.

Authors:  Min Sup Song; Su Jung Song; So Yeon Kim; Hyun Jung Oh; Dae-Sik Lim
Journal:  EMBO J       Date:  2008-06-19       Impact factor: 11.598

2.  Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras.

Authors:  David Matallanas; David Romano; Fahd Al-Mulla; Eric O'Neill; Waleed Al-Ali; Piero Crespo; Brendan Doyle; Colin Nixon; Owen Sansom; Matthias Drosten; Mariano Barbacid; Walter Kolch
Journal:  Mol Cell       Date:  2011-12-23       Impact factor: 17.970

3.  RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family.

Authors:  Kristin Eckfeld; Luke Hesson; Michele D Vos; Ivan Bieche; Farida Latif; Geoffrey J Clark
Journal:  Cancer Res       Date:  2004-12-01       Impact factor: 12.701

Review 4.  The RASSF1A tumor suppressor.

Authors:  Howard Donninger; Michele D Vos; Geoffrey J Clark
Journal:  J Cell Sci       Date:  2007-09-15       Impact factor: 5.285

5.  RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells.

Authors:  Jessica J Mezzanotte; Victoria Hill; M Lee Schmidt; Thoraia Shinawi; Stella Tommasi; Dietmar Krex; Gabriele Schackert; Gerd P Pfeifer; Farida Latif; Geoffrey J Clark
Journal:  Epigenetics       Date:  2014-11       Impact factor: 4.528

6.  Role of the tumor suppressor RASSF2 in regulation of MST1 kinase activity.

Authors:  Hoogeun Song; Sangphil Oh; Hyun Jung Oh; Dae-Sik Lim
Journal:  Biochem Biophys Res Commun       Date:  2009-12-04       Impact factor: 3.575

Review 7.  Inside and out: the activities of senescence in cancer.

Authors:  Pedro A Pérez-Mancera; Andrew R J Young; Masashi Narita
Journal:  Nat Rev Cancer       Date:  2014-07-17       Impact factor: 60.716

8.  CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer.

Authors:  Manuel Irimia; Mario F Fraga; Montserrat Sanchez-Cespedes; Manel Esteller
Journal:  Oncogene       Date:  2004-11-11       Impact factor: 9.867

9.  A comprehensive survey of Ras mutations in cancer.

Authors:  Ian A Prior; Paul D Lewis; Carla Mattos
Journal:  Cancer Res       Date:  2012-05-15       Impact factor: 12.701

Review 10.  The Ras-association domain family (RASSF) members and their role in human tumourigenesis.

Authors:  Louise van der Weyden; David J Adams
Journal:  Biochim Biophys Acta       Date:  2007-07-04
View more
  38 in total

Review 1.  Intracellular and intercellular signaling networks in cancer initiation, development and precision anti-cancer therapy: RAS acts as contextual signaling hub.

Authors:  Peter Csermely; Tamás Korcsmáros; Ruth Nussinov
Journal:  Semin Cell Dev Biol       Date:  2016-07-06       Impact factor: 7.727

2.  RASSF1A Deficiency Enhances RAS-Driven Lung Tumorigenesis.

Authors:  M Lee Schmidt; Katharine R Hobbing; Howard Donninger; Geoffrey J Clark
Journal:  Cancer Res       Date:  2018-05-07       Impact factor: 12.701

3.  The dynamic mechanism of RASSF5 and MST kinase activation by Ras.

Authors:  Tsung-Jen Liao; Hyunbum Jang; Chung-Jung Tsai; David Fushman; Ruth Nussinov
Journal:  Phys Chem Chem Phys       Date:  2017-03-01       Impact factor: 3.676

Review 4.  Biology, pathology, and therapeutic targeting of RAS.

Authors:  J Matthew Rhett; Imran Khan; John P O'Bryan
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

5.  Detection of Endogenous RASSF1A Interacting Proteins.

Authors:  Howard Donninger; Desmond Harrell-Stewart; Geoffrey J Clark
Journal:  Methods Mol Biol       Date:  2021

Review 6.  Oncogenic Ras Isoforms Signaling Specificity at the Membrane.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  Cancer Res       Date:  2017-12-22       Impact factor: 12.701

Review 7.  Intrinsic protein disorder in oncogenic KRAS signaling.

Authors:  Ruth Nussinov; Hyunbum Jang; Chung-Jung Tsai; Tsung-Jen Liao; Shuai Li; David Fushman; Jian Zhang
Journal:  Cell Mol Life Sci       Date:  2017-06-08       Impact factor: 9.261

8.  Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma.

Authors:  Fazal Shirazi; Richard J Jones; Ram K Singh; Jianxuan Zou; Isere Kuiatse; Zuzana Berkova; Hua Wang; Hans C Lee; Samuel Hong; Larry Dick; Nibedita Chattopadhyay; Robert Z Orlowski
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-03       Impact factor: 11.205

Review 9.  MST1/MST2 Protein Kinases: Regulation and Physiologic Roles.

Authors:  Jacob A Galan; Joseph Avruch
Journal:  Biochemistry       Date:  2016-09-26       Impact factor: 3.162

Review 10.  Pumping the brakes on RAS - negative regulators and death effectors of RAS.

Authors:  Desmond R Harrell Stewart; Geoffrey J Clark
Journal:  J Cell Sci       Date:  2020-02-10       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.